By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Kythera Biopharmaceuticals, Inc. 

30930 Russell Ranch Road

Westlake Village  California  91362  U.S.A.
Phone: 818-587-4500 Fax: 818-587-4591


SEARCH JOBS

KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Our objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. Our initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kythera.com.

OUR FOUNDING: KYTHERA Biopharmaceuticals was founded in 2005 on the premise on building a new kind of biotechnology company – one aimed squarely at bringing great science, clinical rigor and real innovation to the growing area of aesthetic medicine.


OUR INSPIRATION: KYTHERA Biopharmaceuticals, Inc. is named after an island off the coast of southern Greece, in the Mediterranean Sea. Southernmost of the Ionian Islands, the island of Kythera was the chief center for the worship of Aphrodite, the Greek goddess of beauty and love. Our colors symbolize sky blue and sand.

OUR MANAGEMENT TEAM: We have a highly experienced management team, many of whom have played a leadership role in securing FDA approval of marquee aesthetic products, such as BOTOX® and JUVEDERM®, and in successfully commercializing established biotechnology products such as Aranesp®, NEUPOGEN® and Neulasta®.




Key Statistics


Email:
Ownership: Public

Web Site: Kythera
Employees:
Symbol: KYTH
 









Company News
Allergan (AGN) And Kythera (KYTH) Announce That Pending Transaction Will Now Be For All-Cash Consideration 8/5/2015 8:15:53 AM
Allergan (AGN) And Kythera (KYTH) Announce Early Termination Of Hart-Scott-Rodino Waiting Period For Allergan's Pending Acquisition Of KYTHERA 7/28/2015 12:41:10 PM
Kythera (KYTH) Grants Stock Options Under Inducement Program 6/17/2015 7:24:04 AM
Allergan (AGN) Coughs Up $2.1 Billion for Double-Chin Drugmaker Kythera (KYTH) 6/17/2015 5:56:07 AM
Kythera (KYTH) To Present At The Bank of America (BAC) Merrill Lynch 2015 Health Care Conference 5/11/2015 10:33:45 AM
Kythera (KYTH) Releases First Quarter 2015 Operating Results And Progress Update 5/8/2015 7:42:25 AM
Kythera (KYTH) Grants Stock Options Under Inducement Program 5/7/2015 7:58:29 AM
Kythera (KYTH) To Release First Quarter 2015 Operating Results 5/1/2015 8:42:58 AM
Kythera (KYTH) Announces FDA Approval Of KYBELLA (Also Known As ATX-101) 4/30/2015 5:58:16 AM
Kythera (KYTH) Grabs FDA Approval for Chin Fat-Busting Drug 4/30/2015 5:56:49 AM
12345678910...
//-->